Interní Med. 2007; 9(5): 230-232 [Prakt. lékáren. 2006; 2(3): 114-117]

Antiresoptive and osteoanabolic medications - mechanisms of the effect, therapeutic value

Mgr. Šárka Blažková, Mgr. Magda Vytřísalová, doc. RNDr. Jiří Vlček CSc
Katedra sociální a klinické farmacie, Farmaceutická fakulta, Univerzita Karlova, Hradec Kralové

Osteoporosis is a chronic metabolic disease of skeleton with serious clinical, social and economical consequences. It is possible to prevent and treat it successfully. The treatment goal is to prevent fractures by an increase in amount and quality of bone matrix. The treatment is longstanding and its result depends on patient cooperation. Medications for treatment of postmenopausal osteoporosis that decrease the risk of vertebral and extra vertebral fractures and enable an improvement of bone matrix are available.

Keywords: osteoporosis, antiresorptive therapy, osteoanabolics

Published: June 21, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Blažková Š, Vytřísalová M, Vlček J. Antiresoptive and osteoanabolic medications - mechanisms of the effect, therapeutic value. Interní Med. 2007;9(5):230-232.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Black M, Cummings R, Karpf B, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541. Go to original source... Go to PubMed...
    2. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517-523. Go to original source... Go to PubMed...
    3. Ettinger B, Black D, Mitlak B, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-645. Go to original source... Go to PubMed...
    4. Hála T. Ibandronat v léčbě postmenopauzální osteoporózy. Farmakoterapie 2005; 5: 413-419.
    5. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544-564. Go to original source...
    6. Chesnut CH, Ettinger M, Miller P, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21: 391-401. Go to original source... Go to PubMed...
    7. Chesnut CH 3rd, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109: 267-276. Go to original source... Go to PubMed...
    8. Kutílek Š, Feřtek D, Hála T a kol. Nové perspektivy v léčbě osteoporózy. Farmakoterapie 2005; 5: 429-433.
    9. Neer M, Arnaud D, Zanchetta R, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441. Go to original source... Go to PubMed...
    10. Péréz-López F. Postmenopausal osteoporosis and alendronate. Maturitas 2004; 48: 179-192. Go to original source... Go to PubMed...
    11. Reginster J. et.al. Strontiumranelate in osteoporosis. Curr Pharm Design 2002; 8: 1907-1916. Go to original source... Go to PubMed...
    12. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165: 2414-2419. Go to original source... Go to PubMed...
    13. Štěpán J. Algoritmus diagnostiky a léčby osteoporózy. Farmakoterapie 2005; 5: 485-494.
    14. Štěpán J. Možnosti zásahu do poruch metabolizmu kostí při osteoporóze. Remedia 2003; 14: 244-250.
    15. Štěpán J, Doležal T. Calcitonium (kalcitonin). Remedia 2004; 14: 218-224. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.